mAbs have been shown to block the effects of PD-1/PD-L1 interactions, resulting in a durable antitumor response and long-term remission in certain patients with a broad spectrum of cancers, including lymphoma, melanoma, lung cancer, bladder cancer, and renal cancer [3]. Here, PDCD1 is linked to cancer.